- Policy
- Incentive-paid items for generic substitution fell to 12,757
- by Lee, Hye-Kyung Aug 11, 2021 05:58am
- 12,757 items were found to be eligible for incentives of 30% of the difference in drug prices if pharmacies dispense generic substitution, which is cheaper than prescription drugs. It decreased 48 items compared to the previous month. The HIRA recently guided the 'Billing Method of Drugs Subjected to Incentives for low-price generic substitu
- Policy
- Pfizer is working hard to introduce Prevenar-20 in Korea
- by Lee, Tak-Sun Aug 10, 2021 05:54am
- Pfizer, which supplies Prevenar-13, pneumococcal vaccine that ranks overwhelmingly at the top of the domestic market, is also working hard to introduce the next-generation vaccine. It started clinical trials for East Asians to introduce Prevenar-20, which was approved by the U.S. Food and Drug Administration (FDA) in June. Prevenar-20 h
- Policy
- Supply of Oseltamivir has declined 55% since COVID outbreak
- by Lee, Hye-Kyung Aug 10, 2021 05:54am
- After COVID-19 epidemic, the supply of respiratory medicine has dropped by nearly half. According to the HIRA's "Medicine Distribution Newsletter No. 1" published on the 5th, the supply of respiratory drugs in spring and winter since 2020 decreased by 40.6% compared to the same period last year, and the supply of Oseltamivir used to treat flu
- Policy
- Vaccination agencies are expected to work too hard in Oct
- by Lee, Tak-Sun Aug 10, 2021 05:54am
- Confusion is expected in October, when COVID vaccinations and flu vaccinations overlap, due to a significant increase in the work of inoculation institutions. In October, the largest number of people are scheduled to receive the second round of COVID vaccinations, and vaccinations to prevent seasonal flu will also begin in earnest. Front-l
- Policy
- It will be reviewed by the Regulatory Reform Committee
- by Lee, Jeong-Hwan Aug 9, 2021 06:02am
- Whether or not to introduce the "no change in manufacturing" policy of consignment generic, which is being opposed by the domestic pharmaceutical industry, will eventually be decided based on the results of the Regulatory Reform Committee review. The MFDS finished collecting opinions on the related industries by March this year after announc
- Policy
- Benefits for Imotun, Tagen-F and Legalon have been deleted
- by Lee, Hye-Kyung Aug 9, 2021 06:01am
- As it was classified as a health functional food in major foreign countries, it was decided to delete the benefit of four already registered medicines. However, Hanlim's Entelon, (Vitis vinifera) can be reimbursed only for lymph edema supplementary therapy due to breast cancer treatment. The remaining two indications, blood circulation, retin
- Policy
- No. of refunded RSA drugs become 23 with addition of Onivyde
- by Lee, Hye-Kyung Aug 9, 2021 06:00am
- With the new addition of Servier Korea's pancreatic cancer treatment 'Onivyde (irinotecan liposome)' that was approved for reimbursement, a total of 23 drugs are now being covered under the Risk-sharing Agreement (RSA) scheme. Patients who take RSA drugs need to bear the full cost of the drug, then request refunds to the applicable pharmaceut
- Policy
- It will spend ₩2.2 trillion to become a vaccine power
- by Lee, Jeong-Hwan Aug 9, 2021 06:00am
- President Moon Jae-in has announced that he would leap forward into a 'global vaccine production, the Big Five' by 2025. It also announced plans to select vaccines as one of the 'three major national strategic technologies' along with semiconductors and batteries and invest &8361;2.2 trillion over the next five years. On the 5th, Presi
- Policy
- Attention is focused on licensing domestic vaccines
- by Lee, Jeong-Hwan Aug 9, 2021 06:00am
- As the supply price of COVID vaccines, which relies entirely on imported products, is confirmed to increase next year's supply price in Korea, it is necessary to develop the vaccine within this year. Attention is focusing on the development status of Korean pharmaceutical bio companies, which are about to undergo phase 3 clinical trials, w
- Policy
- PBAC results on Leclaza that was listed in 165 days show...
- by Lee, Hye-Kyung Aug 6, 2021 06:05am
- ‘Leclaza tab. (lazertinib mesylate monohydrate),' the 31st novel drug to be developed in Korea that received approval for insurance benefit in only 165 days after its approval, was reviewed as a 'new treatment alternative for non-small cell lung cancer patients' in the evaluation process for assessing the reasonableness of the medical care ben
